[go: up one dir, main page]

MX2010005683A - Conjugados de anticuerpos anti-rg-1. - Google Patents

Conjugados de anticuerpos anti-rg-1.

Info

Publication number
MX2010005683A
MX2010005683A MX2010005683A MX2010005683A MX2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A MX 2010005683 A MX2010005683 A MX 2010005683A
Authority
MX
Mexico
Prior art keywords
antibodies
conjugates
partner
cytotoxins
internalized
Prior art date
Application number
MX2010005683A
Other languages
English (en)
Inventor
David J King
Josephine M Cardarelli
Chin Pan
Jonathan A Terrett
Sanjeev Gangwar
Chetana Rao-Naik
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005683(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010005683A publication Critical patent/MX2010005683A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen anticuerpos anti-RG-1 fragmentos de anticuerpo o miméticos de anticuerpo conjugados a moléculas asociadas, tales como fármacos, radioisótopos y citotoxinas, en donde la molécula asociada ejerce su efecto independientemente de si el conjugado unido a RG-1 es internalizado dentro de una célula seleccionada, los cuales son útiles para tratar cánceres.
MX2010005683A 2007-11-30 2008-11-26 Conjugados de anticuerpos anti-rg-1. MX2010005683A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30
PCT/US2008/084899 WO2009073524A2 (en) 2007-11-30 2008-11-26 Conjugates of anti-rg-1 antibodies

Publications (1)

Publication Number Publication Date
MX2010005683A true MX2010005683A (es) 2010-06-11

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005683A MX2010005683A (es) 2007-11-30 2008-11-26 Conjugados de anticuerpos anti-rg-1.

Country Status (18)

Country Link
US (1) US20110020329A1 (es)
EP (1) EP2211908A2 (es)
JP (1) JP2011505371A (es)
KR (1) KR20100101122A (es)
CN (1) CN101951960A (es)
AR (1) AR069746A1 (es)
AU (1) AU2008331507A1 (es)
BR (1) BRPI0819765A2 (es)
CA (1) CA2707443A1 (es)
CL (1) CL2008003525A1 (es)
CO (1) CO6210734A2 (es)
EA (1) EA201000921A1 (es)
IL (1) IL206060A0 (es)
MX (1) MX2010005683A (es)
NZ (1) NZ586514A (es)
TW (1) TW200930407A (es)
WO (1) WO2009073524A2 (es)
ZA (1) ZA201003729B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007000387A (es) * 2004-07-16 2007-03-28 Micromet Ag Polipeptidos de expresion mejorada.
MX2011004625A (es) 2008-11-03 2011-07-20 Syntarga Bv Analogos cc-1065 novedosos y sus conjugados.
EP3056203B1 (en) 2010-04-21 2017-12-13 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
CN103153339B (zh) * 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
PT3092010T (pt) 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
RU2685728C2 (ru) * 2014-01-29 2019-04-23 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения
IL316357A (en) * 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
WO1991016324A1 (en) * 1990-04-25 1991-10-31 The Upjohn Company Novel cc-1065 analogs
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DE69533277T2 (de) * 1994-04-22 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivat
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
JP2005502703A (ja) * 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2005010048A2 (en) * 2003-07-22 2005-02-03 Schering Aktiengesellschaft Rg1 antibodies and uses thereof
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2416136T3 (es) * 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
WO2007059404A2 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
ES2469676T3 (es) * 2006-05-25 2014-06-18 Bayer Intellectual Property Gmbh Complejos moleculares dim�ricos

Also Published As

Publication number Publication date
US20110020329A1 (en) 2011-01-27
CA2707443A1 (en) 2009-06-11
WO2009073524A2 (en) 2009-06-11
CO6210734A2 (es) 2010-10-20
NZ586514A (en) 2012-05-25
EA201000921A1 (ru) 2010-12-30
EP2211908A2 (en) 2010-08-04
AR069746A1 (es) 2010-02-17
ZA201003729B (en) 2011-08-31
AU2008331507A1 (en) 2009-06-11
CL2008003525A1 (es) 2010-01-22
WO2009073524A3 (en) 2009-12-10
IL206060A0 (en) 2010-11-30
JP2011505371A (ja) 2011-02-24
KR20100101122A (ko) 2010-09-16
TW200930407A (en) 2009-07-16
CN101951960A (zh) 2011-01-19
BRPI0819765A2 (pt) 2015-05-05

Similar Documents

Publication Publication Date Title
MX2010005683A (es) Conjugados de anticuerpos anti-rg-1.
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
UA95959C2 (en) Leptomycin derivatives
MX2011010469A (es) Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
IN2009KN02404A (es)
WO2006124737A3 (en) Molecular constructs suitable for targeted conjugates
WO2005117986A3 (en) Antibody drug conjugates and methods
EP2408470A4 (en) SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2010115629A3 (en) Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
GEP20196956B (en) Anti-gcc antibody molecules and related compositions and methods
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
TN2014000148A1 (en) Antigen binding protein and its use as addressing product for the treatment of cancer
BR112013023015A8 (pt) conjugado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina.
MY145058A (en) Prlr-specific antibody and uses thereof
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.
MX2023014282A (es) Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33).
MX2023014683A (es) Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos.
CY1116022T1 (el) Μονοκλωνικα αντισωματα τα οποια δεσμευουν ton β7η6 και χρησεις αυτων

Legal Events

Date Code Title Description
FA Abandonment or withdrawal